Close Menu

NEW YORK – Natera reported after the close of the market on Wednesday a 19 percent increase in third quarter revenues, driven by increased sales of its Panorama noninvasive prenatal and Horizon carrier screening tests.

"Q3 was in many ways a transformational quarter for Natera," said CEO Steve Chapman in a statement. "We continued to see strong momentum in volume growth and improved average selling price per test."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.